15.10
price up icon1.55%   0.23
after-market Dopo l'orario di chiusura: 15.10
loading
Precedente Chiudi:
$14.87
Aprire:
$14.77
Volume 24 ore:
266.22K
Relative Volume:
1.08
Capitalizzazione di mercato:
$673.00M
Reddito:
$84.82M
Utile/perdita netta:
$-21.43M
Rapporto P/E:
-16.97
EPS:
-0.89
Flusso di cassa netto:
$-27.23M
1 W Prestazione:
+2.44%
1M Prestazione:
+6.64%
6M Prestazione:
-11.95%
1 anno Prestazione:
+176.05%
Intervallo 1D:
Value
$14.77
$15.22
Intervallo di 1 settimana:
Value
$14.19
$15.22
Portata 52W:
Value
$4.69
$20.90

Y Mabs Therapeutics Inc Stock (YMAB) Company Profile

Name
Nome
Y Mabs Therapeutics Inc
Name
Telefono
212-847-9841
Name
Indirizzo
230 PARK AVENUE, NEW YORK, NY
Name
Dipendente
100
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-08
Name
Ultimi documenti SEC
Name
YMAB's Discussions on Twitter

Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-08-16 Iniziato Cantor Fitzgerald Overweight
2024-06-28 Iniziato Truist Buy
2023-05-10 Aggiornamento Wedbush Neutral → Outperform
2023-04-03 Downgrade Guggenheim Buy → Neutral
2023-01-27 Downgrade Morgan Stanley Equal-Weight → Underweight
2023-01-05 Downgrade Cowen Outperform → Market Perform
2022-12-02 Downgrade BofA Securities Buy → Neutral
2022-10-31 Downgrade JP Morgan Neutral → Underweight
2022-10-31 Downgrade Wedbush Outperform → Neutral
2022-07-06 Ripresa Canaccord Genuity Buy
2022-06-24 Iniziato BMO Capital Markets Outperform
2022-02-03 Ripresa Guggenheim Buy
2021-11-19 Ripresa Morgan Stanley Equal-Weight
2021-11-16 Downgrade JP Morgan Overweight → Neutral
2021-05-07 Aggiornamento BofA Securities Neutral → Buy
2021-04-23 Ripresa Cowen Outperform
2021-03-22 Ripresa JP Morgan Overweight
2021-01-15 Downgrade BofA Securities Buy → Neutral
2020-11-09 Reiterato H.C. Wainwright Buy
2020-05-05 Iniziato Barclays Overweight
2020-05-01 Iniziato Janney Buy
2020-04-29 Iniziato Morgan Stanley Equal-Weight
2019-12-24 Iniziato JP Morgan Overweight
2019-11-20 Iniziato Guggenheim Buy
2019-09-04 Iniziato Wedbush Outperform
2019-04-01 Iniziato H.C. Wainwright Buy
2018-10-16 Iniziato BTIG Research Buy
2018-10-16 Iniziato BofA/Merrill Buy
Mostra tutto

Y Mabs Therapeutics Inc Borsa (YMAB) Ultime notizie

pulisher
09:06 AM

(YMAB) Trading Advice - Stock Traders Daily

09:06 AM
pulisher
04:19 AM

Vanguard Group Inc's Strategic Acquisition in Y-mAbs Therapeutics Inc - GuruFocus.com

04:19 AM
pulisher
12:49 PM

Y-mAbs enters Japan market with Nobelpharma for cancer therapy By Investing.com - Investing.com Canada

12:49 PM
pulisher
Nov 04, 2024

Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan - The Manila Times

Nov 04, 2024
pulisher
Nov 02, 2024

Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 02, 2024
pulisher
Nov 01, 2024

Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know - MSN

Nov 01, 2024
pulisher
Nov 01, 2024

Y-mAbs Therapeutics (YMAB) Scheduled to Post Quarterly Earnings on Friday - Defense World

Nov 01, 2024
pulisher
Nov 01, 2024

Y-mAbs Therapeutics (YMAB) Scheduled to Post Earnings on Friday - MarketBeat

Nov 01, 2024
pulisher
Oct 30, 2024

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights - Benzinga

Oct 30, 2024
pulisher
Oct 29, 2024

Y-mAbs Therapeutics Investors Get Final OK For $19.7M Deal - Law360

Oct 29, 2024
pulisher
Oct 29, 2024

Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail

Oct 29, 2024
pulisher
Oct 27, 2024

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Oct 27, 2024
pulisher
Oct 25, 2024

Objective long/short (YMAB) Report - Stock Traders Daily

Oct 25, 2024
pulisher
Oct 25, 2024

Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast - The Manila Times

Oct 25, 2024
pulisher
Oct 25, 2024

Y-Mabs Therapeutics Inc (YMAB-Q) QuotePress Release - The Globe and Mail

Oct 25, 2024
pulisher
Oct 24, 2024

13,566 Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Bought by SG Americas Securities LLC - Defense World

Oct 24, 2024
pulisher
Oct 21, 2024

Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers (NASDAQ:YMAB) - Seeking Alpha

Oct 21, 2024
pulisher
Oct 18, 2024

AQR Capital Management LLC Makes New Investment in TreeHouse Foods, Inc. (NYSE:THS) - Defense World

Oct 18, 2024
pulisher
Oct 16, 2024

Cubist Systematic Strategies LLC Has $80,000 Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Oct 16, 2024
pulisher
Oct 16, 2024

Cubist Systematic Strategies LLC Takes Position in Seer, Inc. (NASDAQ:SEER) - Defense World

Oct 16, 2024
pulisher
Oct 16, 2024

Summit Materials, Inc. (NYSE:SUM) Shares Bought by SG Americas Securities LLC - Defense World

Oct 16, 2024
pulisher
Oct 15, 2024

Pediatric Oncology Drugs Market Size, Share, Growth Insights - openPR

Oct 15, 2024
pulisher
Oct 14, 2024

(YMAB) On The My Stocks Page - Stock Traders Daily

Oct 14, 2024
pulisher
Oct 13, 2024

Millennium Management LLC Boosts Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - MarketBeat

Oct 13, 2024
pulisher
Oct 11, 2024

Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 5.7%Still a Buy? - MarketBeat

Oct 11, 2024
pulisher
Oct 09, 2024

Y-mAbs Therapeutics Inc (YMAB) Q2 2024 Earnings Call Highlights: Revenue Growth Driven by ... By GuruFocus - Investing.com Canada

Oct 09, 2024
pulisher
Oct 09, 2024

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Purchased by Dimensional Fund Advisors LP - MarketBeat

Oct 09, 2024
pulisher
Oct 08, 2024

Cubist Systematic Strategies LLC Sells 71,189 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - MarketBeat

Oct 08, 2024
pulisher
Oct 05, 2024

Squarepoint Ops LLC Acquires 74,452 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Oct 05, 2024
pulisher
Oct 05, 2024

Squarepoint Ops LLC Has $1.53 Million Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - MarketBeat

Oct 05, 2024
pulisher
Oct 04, 2024

Long Term Trading Analysis for (YMAB) - Stock Traders Daily

Oct 04, 2024
pulisher
Oct 03, 2024

Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 6.1%Here's What Happened - MarketBeat

Oct 03, 2024
pulisher
Oct 03, 2024

Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Down 6.1% - Defense World

Oct 03, 2024
pulisher
Oct 03, 2024

Point72 Asset Management L.P. Sells 1,168,155 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - MarketBeat

Oct 03, 2024
pulisher
Oct 02, 2024

Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 6.5% - Defense World

Oct 02, 2024
pulisher
Oct 02, 2024

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World

Oct 02, 2024
pulisher
Oct 02, 2024

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $21.14 Average PT from Analysts - MarketBeat

Oct 02, 2024
pulisher
Oct 01, 2024

Y-mAbs to Participate in Upcoming Investor Conferences in October - The Manila Times

Oct 01, 2024
pulisher
Sep 30, 2024

Y-mAbs Therapeutics' SWOT analysis: innovative cancer therapy stock faces pivotal year - Investing.com

Sep 30, 2024
pulisher
Sep 29, 2024

Radiotheranostics Revolution: What to Expect from the 2024 Global Market As Discussed In New Market Researc... - WhaTech

Sep 29, 2024
pulisher
Sep 25, 2024

While shareholders of Y-mAbs Therapeutics (NASDAQ:YMAB) are in the black over 1 year, those who bought a week ago aren't so fortunate - Yahoo Finance

Sep 25, 2024
pulisher
Sep 24, 2024

Jamf (NASDAQ:JAMF) Shares Gap Down to $18.70 - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

Needham maintains Buy rating on Jamf shares with no price target change - Investing.com India

Sep 24, 2024
pulisher
Sep 24, 2024

Jamf (NASDAQ:JAMF) Earns “Market Outperform” Rating from JMP Securities - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Jamf's (JAMF) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

272 Capital LP Acquires 44,486 Shares of Jamf Holding Corp. (NASDAQ:JAMF) - MarketBeat

Sep 24, 2024
pulisher
Sep 23, 2024

Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 4.7% - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Stock Surge: Y-Mabs Therapeutics Inc (YMAB) Closes at 13.73, Marking a -1.93 Increase/Decrease - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

Examining the Potential Price Growth of Jamf Holding Corp (JAMF) - Knox Daily

Sep 23, 2024
pulisher
Sep 23, 2024

How To Trade (YMAB) - Stock Traders Daily

Sep 23, 2024
pulisher
Sep 23, 2024

Nothing is Better Than Y-Mabs Therapeutics Inc (YMAB) stock at the moment - SETE News

Sep 23, 2024

Y Mabs Therapeutics Inc Azioni (YMAB) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Y Mabs Therapeutics Inc Azioni (YMAB) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Gad Thomas
CHIEF BUSINESS OFFICER
Sep 13 '24
Sale
13.47
65,000
875,550
97,681
Gad Thomas
CHIEF BUSINESS OFFICER
Sep 16 '24
Sale
12.97
30,000
389,100
67,681
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Capitalizzazione:     |  Volume (24 ore):